+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 64 Pages
  • June 2024
  • GlobalData
  • Ipsen Group
  • ID: 1291924
Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases, and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and offers products to treat gastrointestinal disorders, and neurodegenerative pathologies. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, and rest of the world. Ipsen is headquartered in Boulogne-Billancourt, France.

Ipsen SA Key Recent Developments

  • May 02, 2024: Ipsen Appoints Keira Driansky as EVP, President of North America
  • Apr 24, 2024: Ipsen Delivers Strong Sales in the First Quarter of 2024, Driven by Growth Platforms & New Medicines, and Confirms Its Full-Year Guidance
  • Apr 02, 2024: Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
  • Oct 26, 2023: Ipsen Delivers Solid Sales Growth in the First Nine Months Of 2023 And Confirms Its Full-Year Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Ipsen SA - Key Facts
  • Ipsen SA - Key Employees
  • Ipsen SA - Key Employee Biographies
  • Ipsen SA - Major Products and Services
  • Ipsen SA - History
  • Ipsen SA - Company Statement
  • Ipsen SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Affiliate
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Ipsen SA - Business Description
  • Product Category: Neuroscience
  • Overview
  • Performance
  • Product Category: Oncology
  • Overview
  • Performance
  • Product Category: Rare Diseases
  • Overview
  • Performance
  • Geographical Segment: Major Western European Countries
  • Performance
  • Geographical Segment: North America
  • Performance
  • Geographical Segment: Other European Countries
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • R&D Overview
  • Ipsen SA - Corporate Strategy
  • Ipsen SA - SWOT Analysis
  • SWOT Analysis - Overview
  • Ipsen SA - Strengths
  • Ipsen SA - Weaknesses
  • Ipsen SA - Opportunities
  • Ipsen SA - Threats
  • Ipsen SA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Ipsen SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 02, 2024: Ipsen Appoints Keira Driansky as EVP, President of North America
  • Apr 24, 2024: Ipsen Delivers Strong Sales in the First Quarter of 2024, Driven by Growth Platforms & New Medicines, and Confirms Its Full-Year Guidance
  • Apr 02, 2024: Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
  • Oct 26, 2023: Ipsen Delivers Solid Sales Growth in the First Nine Months Of 2023 And Confirms Its Full-Year Guidance
  • Sep 01, 2023: Ipsen Announces Change in R&D Leadership: Howard Mayer to retire, Succeeded by Christelle Huguet
  • Jun 20, 2023: IRLAB to Present Data from the Phase IIb Study of Mesdopetam in PD-LIDs at the MDS Congress 2023
  • Jun 06, 2023: Medetia, in Partnership With Institut Imagine and Inserm Transfert, Launches an Innovative Research Program With Ipsen
  • Apr 24, 2023: Ipsen appoints Sandra Silvestri as EVP, chief medical officer and head of global medical affairs, patient safety and patient affairs
  • Feb 09, 2023: Ipsen presents strong full-year 2022 results and guidance for 2023
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Ipsen SA, Key Facts
  • Ipsen SA, Key Employees
  • Ipsen SA, Key Employee Biographies
  • Ipsen SA, Major Products and Services
  • Ipsen SA, History
  • Ipsen SA, Subsidiaries
  • Ipsen SA, Affiliate
  • Ipsen SA, Joint Venture
  • Ipsen SA, Key Competitors
  • Ipsen SA, Ratios based on current share price
  • Ipsen SA, Annual Ratios
  • Ipsen SA, Interim Ratios
  • Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Ipsen SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Ipsen SA, Performance Chart (2019 - 2023)
  • Ipsen SA, Ratio Charts
  • Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Takeda Pharmaceutical Co Ltd
  • Sanofi
  • Recordati SpA
  • Pfizer Inc
  • Novo Nordisk AS
  • Novartis AG
  • Merz Pharma GmbH & Co KgaA
  • Merck Serono Ltd.
  • Merck & Co Inc
  • Ferring Pharmaceuticals Ltd
  • Eli Lilly and Co
  • Eisai Co Ltd
  • Daewoong Co Ltd
  • Bristol-Myers Squibb Co
  • Bayer AG
  • AstraZeneca Plc